Symphony Environmental shares: AIM microcap turnover shadows Monday loan question

Symphony Environmental shares: AIM microcap turnover shadows Monday loan question

July 6, 2026

London, July 6, 2026, 14:24 BST

  • Symphony Environmental priced at 9.00p on some delayed screens, showing a 9.09% gain. Just 11 shares traded. The sell-buy spread was 7.50p/9.00p, according to .
  • No fresh RNS updates posted on company quote pages since the audited results appeared June 30. The annual report and AGM notice expected by July 8.
  • For FY25, revenue dropped 13% to £5.73 million. Gross margin improved, up to 51% from 46%. Operating loss increased to £2.12 million.
  • The key date for investors is Jan. 31, 2027. On that day, £1.5 million in drawn convertible-loan principal can be swapped for shares at 80% of the three-month VWAP unless repaid first.

Symphony Environmental Technologies plc (LON:SYM) jumped early Monday, though hardly any trades went through. Google Finance marked the AIM-listed plastics tech name at 9.00p at 08:36 BST, up 0.75p or 9.09%, but just 11 shares had traded. AJ Bell showed the same quote of 7.50p to 9.00p and matched that 11-share volume.

That’s a 99-pence reported trade, but the value traded was at 9p. With 236.36 million shares out, a 0.75p bump from the 8.25p previous close pushes up the quoted equity by around £1.8 million. So the headline trade isn’t as important as the wide spread and loan overhang here. Symphony’s own AIM Rule 26 page shows 236,363,995 shares issued, none in treasury.

London trading ran a normal session on Monday, open 0800-1630 BST. The FTSE AIM All-Share was flat, up 0.15% to 777.26 at 1402 BST, according to Google Finance. Symphony was still showing a 9.09% gain, but the move looked stale.

Monday tapeSymphony EnvironmentalFTSE AIM All-Share
Last trade9.00p777.26
Change on dayup 9.09%up 0.15%
Volume11 shares
Bid/ask7.50p / 9.00p
52-week low-high5.50p-14.00p693.87-837.43

No new RNS came out from the company on Monday. Symphony’s most recent regulatory update on shareprices.com is still the June 30 audited final results, with earlier releases on June 24 for the Green Economy Mark, June 23 for prelims, and the June 22 convertible loan extension.

Symphony’s June 30 RNS just noted that audited results for the year ending Dec. 31, 2025, are up on its site, and said it expects to post the annual report and AGM notice by July 8. Any trading details were already in the June 23 prelims.

FY result20252024Change
Revenue£5.73 mln£6.59 mln-13.0%
Gross profit£2.95 mln£3.06 mln-3.6%
Gross margin51%46%+5 pp
Operating loss£2.12 mln£1.09 mln+94.5%
Loss before and after tax£2.50 mln£1.34 mln+86.6%

Investors are left to price a split result. Revenue slipped with d2w masterbatch sales falling to £4.56 million from £5.46 million after the Middle East shake-up. d2p revenue stayed flat at £727,000. Gross margin was up, but administration costs jumped to £4.31 million, and Symphony took a £470,000 hit for development-cost impairment.

Chairman Nicolas Clavel said in the results that the group made “a meaningful improvement in the quality of its business” in 2025. He said the group reported a net profit for the first five months of 2026, after a loss a year ago, with revenue up 10%. Investegate

Questions about the balance sheet remain. Symphony said June 22 it pushed back repayment of £1.5 million in unsecured convertible loan principal from SESR Investments Pte Ltd to Jan. 31, 2027. The loan has a 7% annual interest rate and, if not paid back by then, will convert at 80% of the three-month VWAP. SESR owns 19.68% of Symphony.

Loan math checkFigure
Extended loan principal drawn in June 22£1.5 mln
Market cap with shares at 9.00pabout £21.3 mln
Principal as percent of market capabout 7.1%
If 3-month VWAP stayed at 9.00pconversion price 7.20p
New shares issued if converted at that priceabout 20.8 mln
New shares as percent of current sharesabout 8.8%

This is not a forecast. The real conversion price will use the three-month VWAP prior to Jan. 31, 2027. Symphony can choose to repay the loans in full or in part. The preliminary results listed two convertible loan deals at £1.7 million combined, but the June 22 extension RNS showed drawn principal as £1.5 million.

The India option is not included in the Monday quote. Symphony said the Bureau of Indian Standards in India put out IS 19877T:2026 on June 11, replacing IS 17899T. The company’s management in India said they expect testing and certification to land in the second half of 2026, depending on lab work and regulatory timing. Symphony sized the addressable market above $70 million a year if the standard is adopted.

Chief Executive Michael Laurier said in the June 24 Green Economy Mark statement that Symphony is focused on “practical and scalable technologies”. The statement also said the company kept its spot in the London Stock Exchange’s Green Economy Mark for the seventh year in a row, a tag for listed firms with at least 50% of revenue from environmental solutions. Investegate

Symphony’s share register remains tight. On its Rule 26 page, the company lists Somerston Capital at 20.3%, SESR holding 19.68%, Laurier at 11.18%, Elie Basil Victor Dangoor with 6.07% and Quantum Leap 1.1.1 Fund at 4.24%. The firm says 134.1 million shares are not in public hands.

Artur Ślesik

Artur Ślesik is a technology and financial markets journalist at Bez-kabli.pl, covering artificial intelligence, semiconductors, technology stocks and emerging innovations. A graduate of Warsaw University of Technology, he combines a technical background with market analysis to explain how new technologies are shaping industries, businesses and investment trends worldwide.

Stock Market Today

  • Wegovy weight-loss pill hits UK stores, still no NHS coverage
    July 6, 2026, 9:16 AM EDT. Wegovy's weight-loss pill, which includes semaglutide, has landed in UK pharmacies and is selling both in shops and online, but the drug isn't available on the NHS. After regulators approved it on June 11, private doctors are offering it to overweight or obese patients, who need to stick to diet and exercise as well. Taking the pill will cost about £2.30 per day. It's a pill, not an injection, but users need to follow the dosing rules or it won't work. Experts are warning buyers about fake Wegovy pills online, with possible health and fraud dangers. In trials, the 25mg pill cut body weight by 14% to 17% in 64 weeks.